In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(ε-caprolactone) micelles
- 18 November 2005
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 110 (2), 370-377
- https://doi.org/10.1016/j.jconrel.2005.10.008
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancerTransplant International, 2005
- Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances the apoptosis of melanoma cellsEuropean Journal Of Cancer, 2004
- Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer CellsClinical Cancer Research, 2004
- Blockage of 2-Deoxy-d-Ribose-Induced Angiogenesis with Rapamycin Counteracts a Thymidine Phosphorylase-Based Escape Mechanism Available for Colon Cancer under 5-Fluorouracil TherapyClinical Cancer Research, 2004
- Mechanism for Rapid Self-Assembly of Block Copolymer NanoparticlesPhysical Review Letters, 2003
- Rapamycin is an effective inhibitor of human renal cancer metastasis11See Editorial by Sukhatme and Strom, p. 1160.Kidney International, 2003
- Release Kinetics Studies of Aromatic Molecules into Water from Block Polymer MicellesMacromolecules, 1998
- Methoxy poly(ethylene glycol)/ϵ-caprolactone amphiphilic block copolymeric micelle containing indomethacin.Journal of Controlled Release, 1998
- Fluorescence methods in the study of the interactions of surfactants with polymersColloids and Surfaces A: Physicochemical and Engineering Aspects, 1996
- The Mechanism of Action of Cyclosporin A and FK506Clinical Immunology and Immunopathology, 1996